Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples

Therapeutic Drug Monitoring

Volumn 31, Issue 6, 2009, Pages 695-702

  Quaranta, Sylvie ^a   Woloch, Christian ^a   Paccou, Alexandre ^b   Giocanti, Madeleine ^a   Solas, Caroline ^a   Lacarelle, Bruno ^a  

^a TIMONE HOSPITAL   (France)

^b Waters European Headquarters   (France)

Author keywords

Etravirine; HIV; LC MS MS; Raltegravir; Therapeutic drug monitoring

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; ETRAVIRINE; INDINAVIR; LOPINAVIR; METHANOL; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ACCURACY; ARTICLE; CALIBRATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANALYTIC SAMPLE PREPARATION METHODS; ANTI-HIV AGENTS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HIV PROTEASE INHIBITORS; HUMANS; LIMIT OF DETECTION; MICROCHEMISTRY; PYRIDAZINES; PYRROLIDINONES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 73849127379     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181c05adf     Document Type: Article

References (18)

1. Back D, Gibbons S, Khoo S. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006;28:468-473.
2. Gazzard B, Bernard AJ, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006;7:487-503.
3. Best BM, Goicoechea M, Witt MD, et al. A randomized controlled trial of therapeutic drug monitoring in treatment-naive and-experienced HIV-1-infected patients. J Acquir Immune Defic Syndr. 2007;46:433-442.
4. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
5. Yeni P.Rapport 2008: Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts. Médecine-Sciences, Flammarion; 2008.
6. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000; 287:646-650.
7. Merschman SA, Vallano PT, Wenning LA, et al. Determination of the HIV integrase inhibitor, MK-0518 (raltegravir), in human plasma using 96-well liquid-liquid extraction and HPLC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;857:15-24.
8. Madruga JV, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:29-38.
9. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet. 2007;370:39-48.
10. Schöller-Gyüre M, Kakuda TN, De Smedt G, et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol. 2008;66: 508-516.
11. Ter Heine R, Rosing H, van Gorp EC, et al. Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mono-nuclear cell lysate by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2009;49:393-400.
12. Food and Drug Administration, Guidance for Industry on Bioanalytical Method Validation, Federal Register, vol.66, no.100, 23 May 2001, p. 28526.
13. Crommentuyn KM, Rosing H, Nan-Offeringa LG, et al. Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Mass Spectrom. 2003;38:157-166.
14. Crommentuyn KM, Rosing H, Hillebrand MJ, et al. Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;804:359-367. (Pubitemid 38481712)
15. Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;829:82-90.
16. D'Avolio A, Siccardi M, Sciandra M, et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;859: 234-240.
17. Ter Heine R, Rosing H, van Gorp EC, et al. Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mono-nuclear cell lysate by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal. 2009;49:393-400.
18. Markowitz M, Morales-Ramirez JO, Nguyen BY, et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006;43:509-515. Erratum in: J Acquir Immune Defic Syndr. 2007; 44:492.